AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00549874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: oral 8 mg/once daily for 6 months
Study NCT00549874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 20 mg/ once daily for 6 months
Study NCT02553382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary, Herbal
Description: Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
Study NCT02553382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Positive Control
Description: Oat bran blend and wheat bran capsules
Study NCT05352373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: calcium carbonate
Study NCT05352373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sodium bicarbonate
Study NCT03143543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A Lorcaserin (10mg)
Description: 10 mg lorcaserin orally for 7 days
Study NCT03143543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A2 Lorcaserin (20 mg)
Description: 20 mg lorcaserin orally for 7 days
Study NCT02494830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
Study NCT03143543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B Parallel Placebo
Description: Oral placebo vs 10 mg lorcaserin
Study NCT03143543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B2 Parallel Placebo
Description: Oral placebo vs 20 mg lorcaserin
Study NCT00702689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec, STI571(Imatinib Mesylate)
Description: Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)
Study NCT04504279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB-401
Description: Topical application
Study NCT02387346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation
Study NCT04504279 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT01147588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole
Description: 60 mg (2x30-mg capsule), once daily
Study NCT02387346 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Rapid 2 Sham Stimulation
Study NCT02634008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir/ombitasvir
Study NCT01147588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: 80 mg (2x40-mg capsule), once daily
Study NCT02634008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Study NCT02634008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT02634008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Study NCT01695343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB001-A
Study NCT01695343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT01147588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40 mg (1x40-mg capsule), once daily
Study NCT01147588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 300 mg loading dose on Day 1 then 75 mg daily for 28 days
Study NCT03129035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean hystrectomy
Description: Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal
Study NCT03129035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal iliac artery ligation
Description: The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
Study NCT01124162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 100 mg Tablet
Study NCT01124162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozaar®
Description: 100 mg Tablet
Study NCT00762658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Ointment, 5%
Study NCT00762658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Ointment, 2%
Study NCT00762658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Ointment, 0.5%
Study NCT00762658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2728 Ointment Vehicle
Study NCT00762658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betnesol®-V Creme, 0.1%
Study NCT00762658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic® Ointment, 0.1 %
Study NCT00661752 — intervention group
Intervention type: DEVICE
Intervention: quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac
Description: Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
Study NCT03539159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic conventional sized serum eye drops
Description: allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
Study NCT03539159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic micro sized serum eye drops
Description: Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
Study NCT03325088 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial endoscopy
Description: Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
Study NCT02054247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
Study NCT02054247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ultrasound
Description: a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
Study NCT03325088 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial biopsies
Description: 5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
Study NCT02054247 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo ultrasound
Description: same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
Study NCT03988387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support (PS)
Description: Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
Study NCT03457662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: OMC and SDT
Description: OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
Study NCT03629717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided core needle biopsy
Description: Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
Study NCT03629717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
Study NCT03629717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: 20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
Study NCT03629717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1200mg daily
Study NCT03629717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 800 IU daily
Study NCT03211845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional telemonitoring
Description: Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
Study NCT04428905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03325088 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial alveolar enema
Description: For participants who had signed ancillary research consent
Study NCT03696043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axium Steatlh Image Guidance
Description: The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
Study NCT00645723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: intravenous colistin and nebulized colistin
Study NCT00001168 — intervention group
Intervention type: BEHAVIORAL
Intervention: Balanced diet
Description: Dietary studies for the diagnosis of post-prandial hyperlipidemia will include a 3 week period while subjects are on a baseline, isoweight, 15% fat, 42% carbohydrate, normal polyunsaturated fat ratio (0.1-0.3) 250-300 mg cholesterol diet.
Study NCT00016523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Started at 5 ppm and could be increased to 10 ppm
Study NCT00016523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Started at 5 ppm and could be increased to 10 ppm
Study NCT03696043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVD placement
Description: A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
Study NCT03696043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EVD placement
Description: A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
Study NCT04799223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four-foods eating guidelines
Description: To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
Study NCT04799223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No designed-foods eating guidelines
Description: To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
Study NCT01288924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
Study NCT01288924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: NSS 2 ml intravenous before surgery and every 12 hours for two days.
Study NCT03776929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy
Description: Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
Study NCT02936505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporin A (Sandimmun Neoral® or similar):~* Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~* Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; >12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily.
Study NCT04428905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05798338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Analysis of plasma in order to quantify and characterize EVs
Study NCT04428905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04763096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks.
Study NCT01304979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapies
Description: Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
Study NCT01304979 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Indirect therapies that mimic direct therapy intervention
Study NCT02370836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
Study NCT01927991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT (internet-based, cognitive-behavioural therapy)
Description: The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
Study NCT01927991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iCBT (internet-based, cognitive-behavioural therapy)
Description: The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
Study NCT03059329 — intervention group
Intervention type: DRUG
Intervention: Fycompa
Description: The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
Study NCT04987749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study NCT04987749 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study NCT04345016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Once-daily remote foot temperature monitoring
Description: Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
Study NCT00564187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A
Study NCT00564187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
Study NCT00172016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid